Company News

ImmuneOnco (01541.HK) included in the Hang Seng Composite Index

On February 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc.  (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, according to the latest quarterly index series released by Hang Seng Indexes Co., Ltd., ImmuneOnco was included in the Hang Seng Composite Index constituent stocks, which will officially take effect on March 4 (Monday) this year.

The Hang Seng Index is the most influential index in the Hong Kong stock market. Hang Seng Indexes Co., Ltd. is responsible for calculation and quarterly review, and announces adjustments to constituent stocks. The Hang Seng Index is calculated from the market capitalization of a number of constituent stocks (i.e. blue chip stocks) and represents 63% of the 12-month average market capitalization coverage of all listed companies on the Hong Kong Stock Exchange. Historical data shows that the Hang Seng Composite Index has maintained stable growth in the long term. Due to the high degree of certainty, the Hang Seng Composite Index and the constituent stocks included in the index may be favored by the market.

ImmuneOnco was listed on the Hong Kong Stock Exchange on September 5, 2023. It is committed to developing tumor immunotherapy. It is one of the few biotechnology companies in the world that can systematically utilize innate immunity and adaptive immunity. ImmuneOnco's inclusion in the Hang Seng Composite Index will have a positive impact on the company's performance in the capital market. It also marks that ImmuneOnco has met the criteria for inclusion in Southbound Trading.

Founder and Chairman of ImmuneOnco Dr. Tian, Wenzhi said:

    "We are deeply honored that our company to be included in the Hang Seng Composite Index constituent stocks. This is an important milestone in the company development journey. We would like to thank friends and investors for their supports. In the future, we will continue to promote the development of drug candidates to solve a large number of unmet medical needs, continue to expand overseas layout, continue to enrich our innovation pipeline and promote production capacity upgrades, while expanding our talent pool, and strive to create value for shareholders."